Biotech specializing in cortisol-modulating drugs, selling Korlym for Cushing's syndrome and developing relacorilant.
Biotech specializing in cortisol-modulating drugs, selling Korlym for Cushing's syndrome and developing relacorilant.
Nearly all revenue is Korlym, sold in the US through a small number of specialty pharmacies to patients with Cushing's syndrome (too much cortisol), and a generic version has been on sale since 2024. Relacorilant, from the same cortisol-blocking family, is the planned successor, funded from Korlym's profits.
Moat: narrow (IP / patents, process know-how). Deep expertise in cortisol-receptor biology and years of prescriber education in a niche disease.
Headquarters: Menlo Park, California, United States · Founded: 1998 · Employees: 730
Size Corcept Therapeutics (CORT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.42B, the 923rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $67.79 on 18 Nov 2026.
Performance Over six months the shares gained 14.8%, against -0.4% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 20 in its peer set.
Growth Revenue grew 30.0% over the last twelve months (peer median +10.7%); the operating margin is 11.5% (peer median 15.1%).
Valuation It trades at 15.3× forward earnings against a peer median of 19.3× (6th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 10.8 points above its cost of capital (7.7% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $964M | $761M | $675M | $482M | $402M |
| Revenue growth | — | +13% | +40% | +20% | — |
| Gross profit | $950M | $748M | $664M | $476M | $396M |
| EBITDA | $114M | $46.7M | $138M | $108M | $116M |
| Net income | $159M | $98.2M | $140M | $105M | $101M |
| Free cash flow | $195M | $142M | $196M | $127M | $120M |
| Capital expenditure | $3.49M | $211,000 | $2.17M | $139,000 | $413,000 |
| Total debt | $8.99M | $6.11M | $6.94M | $151,000 | $1.14M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Corcept Therapeutics CORT | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 17.5× | 1.6% |
| Recordati REC.MI | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% |
| Xeris Biopharma XERS | $3.10B | +173% | +38% | 13% | 49.7× | 29.5% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CORT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -41.8% | +2.2% | lowest of 21 |
| 6-month return | +14.8% | -0.4% | 8th highest of 20 |
| Distance from 52-week high | -46.4% | -11.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | +30.0% | +10.7% | 6th highest of 21 |
| Operating margin | 11.5% | 15.1% | 9th lowest of 21 |
| Forward P/E | 15.3× | 19.3× | 6th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | 23.9% | 7.2% | 4th most demanding of 15 |
| Growth delivered (Del g) | +16.6% | +9.0% | 3rd highest of 15 |
| Hurdle (Req g minus delivered) | +7.4 pp | -4.5 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | +10.8 pp | +1.7 pp | 5th highest of 19 |
| EV / EBITDA | 62.0× | 22.6× | most expensive of 12 |
| Net debt / EBITDA | -3.2× | 0.6× | 2nd least indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% | +6.6% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |